134 related articles for article (PubMed ID: 15823108)
1. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Int J Gynecol Cancer; 2005; 15(2):255-60. PubMed ID: 15823108
[TBL] [Abstract][Full Text] [Related]
2. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Oncol Rep; 2004 Feb; 11(2):309-13. PubMed ID: 14719060
[TBL] [Abstract][Full Text] [Related]
3. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Gynecol Oncol; 2004 Mar; 92(3):806-12. PubMed ID: 14984945
[TBL] [Abstract][Full Text] [Related]
4. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
6. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.
Ferrandina G; Lauriola L; Zannoni GF; Fagotti A; Fanfani F; Legge F; Maggiano N; Gessi M; Mancuso S; Ranelletti FO; Scambia G
Ann Oncol; 2002 Aug; 13(8):1205-11. PubMed ID: 12181243
[TBL] [Abstract][Full Text] [Related]
7. [Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma].
Lou WZ; Shen K; Zhang Y; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2004 Aug; 39(8):529-32. PubMed ID: 15363351
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Denkert C; Köbel M; Pest S; Koch I; Berger S; Schwabe M; Siegert A; Reles A; Klosterhalfen B; Hauptmann S
Am J Pathol; 2002 Mar; 160(3):893-903. PubMed ID: 11891188
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL
J Chemother; 2003 Aug; 15(4):380-6. PubMed ID: 12962367
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Holzmayer TA; Hilsenbeck S; Von Hoff DD; Roninson IB
J Natl Cancer Inst; 1992 Oct; 84(19):1486-91. PubMed ID: 1359152
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
14. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Seo SS; Song YS; Kang DH; Park IA; Bang YJ; Kang SB; Lee HP
Gynecol Oncol; 2004 Mar; 92(3):927-35. PubMed ID: 14984962
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy.
Wülfing C; Eltze E; von Struensee D; Wülfing P; Hertle L; Piechota H
Eur Urol; 2004 Jan; 45(1):46-52. PubMed ID: 14667515
[TBL] [Abstract][Full Text] [Related]
17. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.
Sakamoto A; Yokoyama Y; Umemoto M; Futagami M; Sakamoto T; Bing X; Mizunuma H
Br J Cancer; 2004 Aug; 91(4):633-8. PubMed ID: 15266333
[TBL] [Abstract][Full Text] [Related]
19. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
